Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

George Young

Urology New York, NY Medical Doctor

NPI 1275559189 CMS profile 102907

1060 Fifth Avenue, New York, NY 10128

Open in the dashboard

General payments

$736

26 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, George Young of New York, NY is reported in the CMS Open Payments database as having received $736 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 27th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $27 1
2023 General $149 2
2022 General $17 1
2021 General $100 5
2020 General $129 5
2019 General $314 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Young
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to George Young were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year George Young Urology median Middle half National median
2019 $314 $480 $147–$1,201 $163
2020 $129 $246 $87–$645 $114
2021 $100 $358 $111–$1,000 $132
2022 $17 $476 $143–$1,263 $149
2023 $149 $560 $168–$1,461 $160
2024 $27 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. NeoTract Inc. $282 10 payments
  2. Ethicon US, LLC $136 1 payment
  3. Endo Pharmaceuticals Inc. $88 4 payments
  4. Myovant Sciences Inc. $83 4 payments
  5. Teleflex LLC $57 3 payments
  6. Ferring Pharmaceuticals Inc. $28 1 payment
  7. Astellas Pharma US Inc $24 1 payment
  8. Janssen Biotech, Inc. $20 1 payment
  9. Boston Scientific Corporation $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $736 26 payments
Products named General payments · program years 2019–2024
  1. UROLIFT $323 12 payments
  2. SURGICEL NU-KNIT $136 1 payment
  3. Echelon Flex $136 1 payment
  4. STRATAFIX $136 1 payment
  5. XIAFLEX $88 4 payments
  6. AVEED $88 4 payments
  7. ORGOVYX $83 4 payments
  8. EDEX $69 3 payments
  9. NOCDURNA $28 1 payment
  10. MYRBETRIQ $24 1 payment
  11. Other $54 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

2,878

Median for Urology: 1,053

Drug cost

$315,594

Median for Urology: $101,464

Branded share of claims

13.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lupron Depot Leuprolide Acetate Brand 74 $221,128
Myrbetriq Mirabegron Brand 110 $58,492
Tamsulosin Hcl Generic 1,486 $16,085
Silodosin Generic 130 $10,732
Finasteride Generic 465 $3,056
Solifenacin Succinate Generic 82 $1,980
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 98 $1,423
Dutasteride Generic 36 $1,227
Celecoxib Generic 137 $381
Amikacin Sulfate Generic 52 $301

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$159,543

Medicare's payments for the services billed

Medicare patients

257

Average age 78

Services billed

2,061

114 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Diabetes 30%
Ischemic heart disease 29%
Cancer 24%
Osteoporosis 24%
Chronic kidney disease 19%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record